Skip to main content

Advertisement

Table 6 Summary of HPV prevalence by source of heterogeneity (Prevalence; 95% confidence interval)

From: Prevalence of human papillomavirus in head and neck cancers in European populations: a meta-analysis

Type of cancer Geographic location Type of samples analysed Type of primer used
Eastern Europe Western Europe Unclear Fixed-biopsy Others Not reported GP5+/GP6+ MY09/MY11 (not GP5+/GP6+) Others Not reported
Base of tongue 50.0%; 95% CI, 23.7% to 76.3% 44.5%; 95% CI, 29.4% to 59.5% 53.7%; 95% CI, 40.9% to 66.6% 41.5%; 95% CI, 26.9% to 56.1% Not applicable 53.7%; 95% CI, 44.6% to 62.8% 50.0%; 95% CI, 23.7% to 76.3% Not applicable 39.5%; 95% CI, 20.2% to 58.8% 53.7%; 95% CI, 44.6% to 62.8%
Hypopharyngeal Not applicablea Not applicableb 60.0%; 95 CI%, 20.3% to 100.0%c 50.0%; 95 CI%, 21.5% to 78.5% 48.9%; 95 CI%, 0.0% to 97.9%d 29.3%; 95 CI%, 12.0% to 46.3%
Laryngeal 27.5%; 95 CI%, 0.0% to 55.1%c 28.0%; 95 CI%, 14.8% to 41.2% Not applicable 32.0%; 95 CI%, 17.0% to 47.1% 19.7%; 95 CI%, 12.8% to 26.6% Not applicable 25.6%; 95 CI%, 5.1% to 46.0% 56.0%; 95 CI%, 0.0% to 100.0%c,d 29.6%; 95 CI%, 4.7% to 54.7% 20.5%; 95 CI%, 14.0% to 26.9%
Oral 34.7%; 95 CI%, 9.4% to 60.0% 21.3%; 95 CI%, 15.0% to 27.7% Not applicable 27.5%; 95% CI, 20.3% to 34.8% 26.6%; 95% CI, 19.8% to 33.3% Not applicable 34.8%; 95 CI%, 17.6% to 52.0% 34.5%; 95 CI%, 14.2% to 54.8% 16.9%; 95 CI%, 0.0% to 34.6%c 16.7%; 95 CI%, 0.0% to 34.6%c
Oropharyngeal 56.9%; 95% CI, 49.5% to 64.3% 33.7%; 95% CI, 24.2% to 43.2% Not applicable 39.6%; 95% CI, 29.7% to 49.5% 33.3%; 95% CI, 20.4% to 46.2% 64.0%; 95% CI, 55.4% to 72.7% 46.8%; 95 CI%, 33.2% to 60.3% 36.5%; 95 CI%, 0.0% to 73.1%c 37.8%; 95 CI%, 15.5% to 60.2% 37.7%; 95 CI%, 19.9% to 55.5%
Pharyngeal 20.0%; 95% CI, 0.0% to 49.4%c 14.3%; 95% CI, 0.7% to 27.9% Not applicable Not applicableb 29.4%; 95 CI%, 0.0% to 58.8%c 29.4%; 95 CI%, 0.0% to 58.8%c 22.1%; 95 CI%, 0.0% to 44.1%c Not applicable
Tongue 12.2%; 95% CI, 0.0% to 24.4% 32.1%; 95% CI, 0.9% to 63.2% Not applicable 34.2%; 95% CI, 0.0% to 68.3% 21.4%; 95% CI, 10.9% to 32.0% Not applicable 12.2%; 95 CI%, 0.0% to 24.4%c Not applicable 33.3%; 95 CI%, 0.0% to 100.0%c,d 21.4%; 95 CI%, 10.9% to 32.0%
Tonsillar 80.4%; 95% CI, 69.7% to 91.1% 64.2%; 95% CI, 54.1% to 74.3% Not applicable 65.0%; 95% CI, 54.2% to 75.8% Not applicable 73.3%; 95% CI, 65.6% to 81.1% 62.4%; 95 CI%, 43.5% to 81.3% 80.3%; 95 CI%, 68.2% to 92.4% 62.6%; 95 CI%, 30.0% to 95.1% 68.7%; 95 CI%, 61.6% to 75.8%
  1. aAll studies investigated patients from Western Europe.
  2. bThe sources of all cancer types were fixed biopsies.
  3. cAdjusted values to reflect prevalence estimates less than 0.0%.
  4. dAdjusted values to reflect prevalence estimates exceeding 100%.